NCT02802943 2022-11-28
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
University Hospital Tuebingen
Phase 2 Completed
Clinical Trials
9 trialsNCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00706992 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00334776 2014-05-21
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Southern California
Phase 2 Completed
NCT00357461 2013-05-15
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT00109811 2013-01-23
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005949 2013-01-16
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00162500 2010-11-10
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Hadassah Medical Organization
Phase 2 Withdrawn